Filters
Results of the BASIS trial demonstrate the efficacy and safety of once-weekly SC marstacimab prophylaxis up to 12 months in male adolescents and adults with severe haemophilia A* (HA) or severe-to-moderately-severe haemophilia B** (HB) with no detectable or documented history of inhibitors against factors VIII or IX, and who were receiving on-demand (OD) or routine prophylaxis (RP) prior to enrolment.
Initiating antiretroviral therapy (ART) with the fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide on the same day of HIV diagnosis appears to promote a high level of engagement in care in Taiwan.
The use of inhaled ciclesonide provides no additional benefit to vaccinated adults exposed to Omicron variants of SARS-CoV-2 in fast-tracking their recovery from acute symptoms, a study has shown.
Getting a COVID-19 shot prior to or during pregnancy reduces the risks of severe maternal disease outcomes and preterm birth, and this protection remains consistent across different variant periods, according to a study from Canada.
Treatment with the novel natriuretic peptide receptor-1 (NPR-1) agonist XXB750 demonstrates a neutral effect on 24-h ambulatory systolic blood pressure (SBP) in patients with resistant hypertension, as shown by the results of a phase II trial.
Adherence to inhaler therapy among adult asthma patients in Singapore is intermediate or poor, reports a study, noting the importance of targeted interventions.
Quality of life (QOL) among patients with systemic lupus erythematosus (SLE) improves following CD19 chimeric antigen receptor (CAR) T cell therapy, with also helps lessen the socioeconomic burden associated with active disease, a study has shown.
A systematic review and meta-analysis conducted by researchers in Singapore support ceftazidime-avibactam (CAZ/AVI) as a primary therapeutic alternative for the treatment of OXA-48–producing carbapenem-resistant Enterobacterales (CRE).
The tricyclic antidepressant nortriptyline is only as good as placebo in terms of reducing symptoms of functional dyspepsia in preselected patients, according to the results of a multicentre randomized controlled trial.
Treatment with the combination of savolitinib plus osimertinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) harbouring EGFR mutation and MET amplification, as shown in the phase III SACHI trial.
